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Abstract: Donepezil is the leading compound for the treatment of Alzheimer’s disease (AD) 
in more than 50 countries. As compared with other conventional acetylcholinesterase inhibitors 
(AChEIs), donepezil is a highly selective and reversible piperidine derivative with AChEI activity 
that exhibits the best pharmacological proﬁ  le in terms of cognitive improvement, responders rate 
(40%–58%), dropout cases (5%–13%), and side-effects (6%–13%) in AD. Although donepezil 
represents a non cost-effective treatment, most studies convey that this drug can provide a modest 
beneﬁ  t on cognition, behavior, and activities of the daily living in both moderate and severe AD, 
contributing to slow down disease progression and, to a lesser exetnt, to delay institutionaliza-
tion. Patients with vascular dementia might also beneﬁ  t from donepezil in a similar fashion to 
AD patients. Some potential effects of donepezil on the AD brain, leading to reduced cortico-
hippocampal atrophy, include the following: AChE inhibition, enhancement of cholinergic 
neurotransmission and putative modulation of other neurotransmitter systems, protection against 
glutamate-induced excitotoxicity, activation of neurotrophic mechanisms, promotion of non-
amyloidodgenic pathways for APP processing, and indirect effects on cerebrovascular function 
improving brain perfusion. Recent studies demonstrate that the therapeutic response in AD is 
genotype-speciﬁ  c. Donepezil is metabolized via CYP-related enzymes, especially CYP2D6, 
CYP3A4, and CYP1A2. Approximately, 15%–20% of the AD population may exhibit an ab-
normal metabolism of AChEIs; about 50% of this population cluster would show an ultrarapid 
metabolism, requiring higher doses of AChEIs to reach a therapeutic threshold, whereas the 
other 50% of the cluster would exhibit a poor metabolism, displaying potential adverse events 
at low doses. In AD patients treated with a multifactorial therapy, including donepezil, the best 
responders are the CYP2D6-related extensive (EM)(*1/*1, *1/*10) (57.47%) and intermediate 
metabolizers (IM)(*1/*3, *1/*5, *1/*6, *7/*10) (25.29%), and the worst responders are the poor 
(PM) (*4/*4)(9.20%) and ultra-rapid metabolizers (UM) (*1xN/*1) (8.04%). Pharmacogenetic 
and pharmacogenomic factors may account for 75%–85% of the therapeutic response in AD 
patients treated with donepezil and other AChEIs metabolized via enzymes of the CYP family. 
The implementation of pharmacogenetic protocols can optimize AD therapeutics. 
Keywords: donepezil, Alzheimer’s disease, vascular dementia, CNS disorders, pharmacokinet-
ics, pharmacodynamics, CYP2D6, pharmacogenetics
Introduction
Donepezil is the number one member of the second generation of acetylcholinesterase 
inhibitors (AChEIs) (ie, donepezil, rivastigmine, galantamine) (Table 1) developed for 
the treatment of Alzheimer’s disease (AD) after the postulation in the early 1980s that 
AD was associated with a central cholinergic deﬁ  cit (Bartus et al 1982; Whitehouse 
et al 1982). The ﬁ  rst generation of AChEIs was represented by physostigmine, tacrine, 
velnacrine, and metrifonate of which only tacrine reached the marked in 1993 with an 
ephemeral life due to pharmacokinetic and pharmacodynamic problems (Giacobini 
2006). After the closure of tacrine production, donepezil became the mainstay of AD Neuropsychiatric Disease and Treatment 2007:3(3) 304
Cacabelos
therapeutics from 1996 up to now. More than 1000 papers have 
been published on the properties of donepezil during the past 
decade (1996–2006). About 800 papers deal with donepezil in 
dementia (>300 clinical trials worldwide) (Table 2), and ap-
proximately 100 papers refer to the role of donepezil in other 
central nervous system (CNS) disorders. At the present time, 
donepezil is the leading compound for AD treatment in the 
world (marketed in 56 countries) (Sugimoto et al 2002). 
Major issues for a drug to be successful include efﬁ  cacy, 
safety, and at least some pharmacoeconomic beneﬁ  t. On 
average, most studies with AChEIs reported by the pharma-
ceutical industry showed a cognitive enhancement of 2–3 
points (vs placebo) in the ADAS-Cog score in clinical trials 
of 12–30 weeks’ duration, with improvement in 12%–58% of 
patients, 5%–73% of drop-outs, and side-effects in 2%–58% 
of cases (Giacobini 2006). As compared with other AChEIs, 
donepezil exhibits the best pharmacological proﬁ  le in terms 
of cognitive improvement (2.8–4.6 vs 0.7–1 points of dif-
ference with placebo in the ADAS-Cog scale), responders 
rate (40%–58%), drop-out cases (5%–13%), and side-effects 
(6%–13%) (Giacobini 2006). Most studies agree that donepe-
zil is a safe drug, although important adverse drug reactions 
Table 1 Pharmacological properties of selected acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease
Properties Tacrine  Donepezil Rivastigmine  Galantamine
Class Aminoacridine  Piperidine  Carbamate  Tertiary  alkaloid
AChE inhibition  Reversible  Reversible  Pseudo-irreversible  Reversible
 Noncompetitive  Noncompetitive  Noncompetitive  Competitive
Dose (mg/day)  80–160  5–10  6–12  16–24
Duration Short-acting  Short-acting  Intermediate-acting  Short-acting
Brain AChE selectivity  125  33  42,000  3,900
IC50 (nmol/L)
Serum BuChE selectivity  7.2  988  54,000  18,600
IC50 (nmol/L)
BuChE/AChE selectivity  0.06  30  1.3  4.8
Cmax (μg/L)  5.1 (10 mg)  7.2 (5 mg)  5.07 (2 mg x 2)  42 (12 mg x 2)
  20.7 (20 mg)  25.6 (10 mg)  14.1 (6 mg x 2)  137 (16 mg x 2)
  33.9 (30 mg)
Tmax (h)  1–2  3–5  0.5–2  0.9–2
AUC (μg/L/h)  2–4  539  15.4 (3 mg x 2)  1.1
      55.9 (6 mg x 2)
T1/2 (h)  1.3  50–80  0.6–2  7–8
Bioavailability (%)  17–37  100  35–40  100
Protein binding (%)  55  96  40  18
Clearance (L/h/kg)  2.42  0.13  1.5 (6 mg bid)  0.34
Vd (L/kg)  3.5–7  14  1.8–2.7  2.64
Cytochrome P450  CYP1A2  CYP2D6  Carbomoylation  CYP2D6
Metabolism CYP2D6  CYP3A4    CYP3A4
Active metabolites  1-hydroxy-tacrine  6-O-desmethyldonepezil  NAP 226–90  Sanguinine
Urine excretion (%)  <3  17  Metabolite  50
Efﬁ  cacy  4.0–5.3 vs 0.8–2.8  2.8–4.6 vs 0.7–1.2  1.9–4.9 vs 0.7–1.2  3.1–3.9 vs 1.73
ADAS-Cog vs Placebo
Adverse effects
Nausea 3+  3+  3+  2+
Vomiting 2+  2+  2+ 2+
Diarrhea 2+  2+  2+ 1+
Dizziness 2+  1+  2+ 1+
Headache 1+ 0  1+  0
Abdominal pain  1+  0  1+  0
Anorexia 2+  1+  1+ 0
Bradycardia 0  0  0  0
Fatigue 0  1+  1+  1+
Muscle clamps  0  1+  0  0
Agitation 2+  1+  0  1+
Dyscrasia 0  0  0  0
Liver dysfunction  3+  0  0  0
Sources: Cacabelos, CIBE Database, 2005; Cacabelos 2005a, b; Bentué-Ferrer et al 2003; Giacobini 2000, 2006.Neuropsychiatric Disease and Treatment 2007:3(3) 305
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(ADRs) have been reported in the international literature 
(Table 3). However, when evaluating efﬁ  cacy and safety issues 
with AChEIs in AD, methological limitations in some studies 
reduce the conﬁ  dence of independent evaluators in the valid-
ity of the conclusions drawn in published reports (Clegg et al 
2001; Lanctôt et al 2003; Hogan et al 2004; Kaduszkiewicz 
et al 2005; Loveman et al 2006). For pharmacoeconomic as-
pects, some studies assessing the cost-effectiveness of ChEIs 
suggest that AChEI therapy provides beneﬁ  t at every stage 
of disease, with better outcomes resulting from persistent, 
uninterrupted treatment (Fillit 2000; Sano 2004; Feldman et al 
2004), whereas other studies indicate that AChEIs are not cost-
effective, with beneﬁ  ts below minimally relevant thresholds or 
cost-neutral (Clegg et al 2001; Wimo 2004; Wimo et al 2004; 
Loveman et al 2006). The average annual cost per person with 
dementia ranges from US$15,000 to US$50,000, depending 
upon disease stage and country, with a lifetime cost per patient 
of more than US$175,000. Approximately, 80% of the global 
costs of dementia (direct and indirect costs) are assumed by 
the patients and/or their families, and 10%–20% of the costs 
of dementia are attributed to pharmacological treatment (Ca-
cabelos 2005a, 2005b). Considering an average survival time 
(from diagnosis to death) of 10 years in optimal conditions,   
receiving 4–6 different drugs/day, a patient with dementia 
expends about US$4500–6000 per year (≈US$50,000 in a 
decade) in medicines. 
Since the past experience in AD therapeutics was regret-
tably unsuccessful, donepezil is a good paradigm to interpret 
the past and to plan ahead future pharmacological challenges 
in order to optimize the treatment of dementia, incorporat-
ing novel data about the impact of pharmacogenetics on AD 
therapeutics and the inﬂ  uence of genetic factors on eﬁ  cacy 
and safety issues. 
Molecular pathology of Alzheimer’s 
disease
AD is a polygenic/multifactorial complex disorder character-
ized by the premature death of neurons. More than 200 dif-
ferent genes distributed across the human genome have been 
potentially involved in the pathogenesis of AD (Cacabelos et al 
2005). The genetic defects identiﬁ  ed in AD during the past 25 
years can be classiﬁ  ed into 3 main categories: (a) Mendelian 
or mutational defects in genes directly linked to AD, including 
(i) 18 mutations in the amyloid beta (Aβ) precursor protein 
(APP) gene (21q21); (ii) 142 mutations in the presenilin 1 
(PS1) gene (14q24.3); and (iii) 10 mutations in the presenilin 
2 (PS2) gene (1q31-q42). (b) Multiple polymorphic variants of 
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Donepezil in dementia
Table 3 Adverse drug reactions reported in clinical trials with donepezil in Alzheimer’s disease and other CNS disorders
ADRs Frequencya Disease
Pain 15%  mAD
Common cold  9%  mAD
Headache 8%  mAD
Fatigue 5%  mAD
Hypertension 5%  mAD
Urinary tract infections  7%–17%  mAD, sAD
Abdominal disturbance  6%  mAD
Stomach upset  6%  mAD
Anorexia 6%  mAD
Bloating 5%  mAD
Hematic and lymphatic disorders   5%  mAD
Metabolic and nutritional disorders  6%  mAD
Musculoskeletal problems  17%–25%  mAD, sAD, DS, DLB
Accidental fall  11%–13%  mAD, sAD
Anxiety 6%–7%  mAD,  sAD
Agitation  24%–56%  mAD, sAD, DS
Insomnia 11%  mAD
Confusion 8%  mAD
Depression 8%  mAD
Dizziness 7%  mAD
Restlessness 5%  mAD
Vertigo 5%  mAD
Accidental injury  6%–11%  mAD, sAD
Gastroenteritis 6%  sAD
Weight loss  15%–20%  mAD, sAD
Diarrhea 9%  mAD,  sAD
Coughing 5%  mAD
Nasal congestion  5%  mAD
Pneumonia 9%–10%  sAD
Cystitis 6%  sAD
Nausea 6%–8%  mAD,  sAD
Asthenia 3%–5%  mAD,  sAD
Accidental bone fracture  6%–8%  mAD, sAD
Constipation 4%  sAD
Skin problems  14%  mAD, sAD, DLB
Hallucinations 5%–6%  mAD,  sAD
Somatosensory alterations  5%  mAD
Urogenital disturbances  24%  mAD
Unusual/abnormal dreams/nightmares  10%–34.3%  mAD, MCI, MS
Cardiovascular dysfunction  30%–40%  mAD, sAD
Lipid metabolism alterations  20%–35%  mAD
Syncope 1%–10%  sAD
Tardive dyskinesia  1%–4%  mAD, SCZ, PSYD
Catatonia <1%  DLB
Pisa syndrome  <1%  mAD, sAD, PD
Athetosis <1%  m/sAD
Parkinsonism <1%  DLB
Neuroleptic malignant syndrome  <1%  mAD, SCZ
Delirium 1%–2%  m/sAD
Extrapyramidal symptoms  1%–5%  PD; SCZ
Toxic hepatitis  <1%  AD
Dyskinetic disorders  <1%  AD
Syncope <1%  AD
Pancreatitis <1%  AD
Seizures 1%–3%  AD
Purpuric rash  <1%  AD
Prolonged effects of anesthesia  <1%  AD
aEstimated values from clinical trials and clinical observations reported in the international literature (n = 112)
Abbreviations: DLB, dementia with Lewy bodies; DS, Down’s syndrome; mAD, Mild-moderate Alzheimer’s disease; MS, multiple sclerosis; PD, Parkinson’s disease; 
PSYD; psychotic disorders; sAD, moderate–severe Alzheimer’s disease; SCZ, schizophrenia.Neuropsychiatric Disease and Treatment 2007:3(3) 310
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risk characterized in more than 200 different genes distributed 
across the human genome can increase neuronal vulnerability 
to premature death (Cacabelos et al 2005). Among these genes 
of susceptibility, the apolipoprotein E (APOE) gene (19q13.2) 
is the most prevalent as a risk factor for AD, especially in 
those subjects harbouring the APOE-4 allele, whereas carriers 
of the APOE-2 allele might be protected against dementia. 
APOE-related pathogenic mechanisms are also associated 
with brain aging and with the neuropathological hallmarks 
of AD. (c) Diverse mutations located in mitochondrial DNA 
(mtDNA) through heteroplasmic transmission can inﬂ  uence 
aging and oxidative stress conditions, conferring phenotypic 
heterogeneity. It is also likely that defective functions of genes 
associated with longevity may inﬂ  uence premature neuronal 
survival, since neurons are potential pacemakers deﬁ  ning 
life span in mammals. All these factors may interact in as yet 
unknown genetic networks leading to a cascade of pathogenic 
events characterized by abnormal protein processing and mis-
folding with subsequent accumulation of abnormal proteins 
(conformational changes), ubiquitin-proteasome system 
dysfunction, excitotoxic reactions, oxidative and nitrosative 
stress, mitochondrial injury, synaptic failure, altered metal 
homeostasis, dysfunction of axonal and dendritic transport and 
chaperone misoperation (Bossy-Wetzel et al 2004; Cacabelos 
2005a, b; Cacabelos et al 2005). Some of these mechanisms 
are common to several neurodegenerative disorders which dif-
fer depending upon the gene(s) affected and the involvement 
of speciﬁ  c genetic networks, together with cerebrovascular 
factors, epigenetic factors, oxidative stress phenomena, and 
environmental conditions (eg, nutrition, toxicity, social fac-
tors) (Bossy-Wetzel et al 2004; Cacabelos et al 2005; Mattson 
and Magnus 2006). The higher the number of defective genes 
involved in AD pathogenesis, the earlier the onset of the dis-
ease, the faster its clinical course and the poorer its therapeutic 
outcome (Cacabelos 2005a, b; Cacabelos et al 2005). 
Although the amyloid hypothesis is recognized as the pri-
mum movens of AD pathogenesis (Selkoe and Podlisny 2002; 
Suh and Checler 2002; Cacabelos et al 2005), mutational 
genetics associated with amyloid precursor protein (APP) 
and presenilin (PS) genes alone (<10% of AD cases) does 
not explain in full the neuropathologic ﬁ  ndings present in 
AD, represented by amyloid deposition in senile plaques and 
vessels (amyloid angiopathy), neuroﬁ  brillary tangle (NFT) 
formation due to hyperphosphorylation of tau protein, synap-
tic and dendritic desarborization and neuronal loss (Goedert 
and Spillantini 2006). These ﬁ  ndings are accompanied by 
neuroinflammatory reactions, oxidative stress, and free 
radical formation probably associated with mitochondrial 
dysfunction, excitotoxic reactions, alterations in cholesterol 
metabolism and lipid rafts, deﬁ  ciencies in neurotransmitters 
(especially acetylcholine) and neurotrophic factor function, 
defective activity of the ubiquitin-proteasome, and chaperone 
systems and cerebrovascular dysregulation (Cacabelos et al 
2005). All these neurochemical events are potential targets 
for treatment; however, it is very unlikely that a single drug 
be able alone to neutralize the complex mechanisms involved 
in neurodegeneration (Cacabelos 2005a, b; Cacabelos et al 
2005; Cacabelos and Takeda 2006). 
The cholinergic hypothesis
Before the understanding of the complex pathology of AD, 
in the late 1970s and early 1980s it was believed that AD-
related memory dysfunction was in part due to a cholinergic 
deﬁ  cit in the brain of affected people due to a loss of neurons 
in the basal forebrain, this giving rise to the cholinergic hy-
pothesis of AD (Bartus et al 1982; Whitehouse et al 1982; 
Francis et al 1999). The role of acetylcholine on memory 
function had been postulated many years before, and it was 
reasonable to think that a cholinergic deﬁ  cit associated with 
an age-related decline in the number of neurons (50%–87%) 
of the nucleus basalis of Meynert accompanied by a reduced 
number of cholinergic synapses in cortical fronto-parietal-
temporal regions and in the entorhinal cortex, might justify 
the memory deﬁ  cit present in AD patients (Bartus et al 1982). 
From the 1950s to the 1980s “the amyloid hypothesis” and 
“the tau hypothesis” were elaborated, and both theories be-
came the dominant and confronted pathogenic mechanisms 
potentially underlying AD-related neurodegeneration (Goed-
ert and Spillantini 2006). However, recent genomic studies 
suggest that amyloid deposition in senile plaques, NFT and 
cholinergic deﬁ  cits are but the phenotypic expression of 
the disease, and that the causative mechanism of premature 
neuronal death should be upstream of all these pathogenic 
events (Cacabelos et al 2005).
Since choline donors (precursors) and acetylcholine itself 
were substances of difﬁ  cult pharmacological management 
(or useless to increase brain cholinergic neurotransmission), 
and, paradoxically, considering that acetylcholinesterase 
activity progressively decreased in AD brains in parallel with 
cognitive deterioration, AChEIs were proposed as an option 
to inhibit acetylcholine degradation in the synaptic cleft and 
to increase choline reuptake at the presynaptic level with 
the aim of enhancing acetylcholine synthesis in presynaptic 
terminals, this facilitating cholinergic neurotransmission 
(Giacobini 2006). The ﬁ  rst candidate to fulﬁ  l this criteria 
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which after its introduction in the market in 1993 soon fell 
out of favor due to its hepatotoxicity and poor tolerability; 
3 years later, in 1996, donepezil was approved by the FDA 
for the treatment of mild-to-moderate cases of AD. The other 
AChEIs, rivastigmine and galantamine, were introduced 
several years later (Giacobini 2006).
Pharmacological properties 
of donepezil
Donepezil, 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-
2-yl]methylpiperidine hydrochloride (E2020), is an indan-
one benzylpiperidine derivative (Sugimoto et al 1995) with 
selective reversible AChEI activity in the CNS and other 
tissues (Nochi et al 1995; Giacobini et al 1996; Sugimoto 
et al 2002). Donepezil is approximately 10 times more potent 
than tacrine as an inhibitor of acetylcholinesterase (AChE), 
and 500–1000-fold more selective for AChE over butyryl-
cholinesterase (BuChE). This compound is slowly absorbed 
from the gastrointestinal tract and has a terminal elimination 
half-life of 50–70 hours in young volunteers (>100 hours in 
elderly subjects) (Ohnishi et al 1993). After extensive me-
tabolization in the liver, the parent compound is 93% bound 
to plasma proteins (Heydorn 1997). 
AChEIs exhibit different afﬁ  nities and selectivity for 
AChE and BuChE; however, most of them display a similar 
potency and clinical efﬁ  cacy at conventional doses, this fact 
suggesting that these compounds may exert their therapeutic 
effects via collateral mechanisms unrelated to or indirectly 
linked with cholinesterase inhibition. Their chemical struc-
tures are also responsible for their pharmacokinetic and 
pharmacodynamic properties (Nordberg and Svensson 1999). 
For instance, physostigmine and rivastigmine are carbamates 
with pseudo-irreversible AChE-BuChE inhibition; tacrine is 
an acridine with reversible inhibition on the AChE-BuChE 
substrates; metrifonate is an organophosphate with irrevers-
ible inhibition of AChE-BuChE; donepezil is a piperidine 
with highly speciﬁ  c, reversible AChE inhibition; galantamine 
is a phenanthrene with reversible inhibition of AChE-BCh; 
and huperzine A is a pyridine with speciﬁ  c, reversible AChE 
inhibition (Giacobini 2006) (Table 1). The order of inhibitory 
potency (IC50) towards AChE activity under optimal assay 
conditions for each AChEI is the following: physostigmine 
(0.67 nM) > rivastigmine (4.4 nM) > donepezil (6.7 nM) > 
TAK-147 (12 nM) > tacrine (77 nM) > ipidacrine (270 nM). 
According to this study performed by Eisai scientists, the 
benzylpiperidine derivatives donepezil and TAK-147 showed 
high selectivity for AChE over BuChE; the carbamate deriva-
tives showed moderate selectivity, while the 4-aminopyridine 
derivatives tacrine and ipidacrine showed no selectivity (Ogura 
et al 2000). More recent studies indicate that donepezil is 
40–500-fold more potent than galantamine in inhibiting 
AChE. Clearance of galantamine from the brain is faster than 
donepezil. Ki values of brain AChE inhibition for galantamine 
and donepezil, respectively, are 7.1–19.1 and 0.65–2.3 μg/g 
in different species, suggesting that for a similar degree of 
brain AChE inhibition, 3–15 times higher galantamine than 
donepezil doses are needed (Geerts et al 2005). 
The pharmacokinetic properties of AChEIs are also differ-
ent. Tacrine, donepezil, and galantamine are metabolized in the 
liver via the cytochrome P450 system (CYP1A2-, CYP2D6-, 
CYP3A4-related enzymes), whereas rivastigmine is metabolized 
through carbomoylation (Table 1). Donepezil potentially may 
interact with drugs metabolized via CYP1A2-, CYP2D6-, and 
CYP3A4-related enzymes; however, formal pharmacokinetic 
studies have revealed no clinically meaningful interactions with 
memantine, risperidone, sertraline, carbidopa/levodopa, theoph-
ylline, furosemide, cimetidine, warfarin, and digoxin (Tiseo 
et al 1998a, b, c, d, e, f; Seltzer 2005). Their half-life also differ 
from 2–4 hours (tacrine, metrifonate, phenserine) to 4–6 hours 
(rivastigmine, galantamine), and 73 hours (donepezil). Bioavail-
ability is maximum for galantamine (100%) and metrifonate 
(90%), both substances showing the lowest plasma protein 
binding (10–20%) in contrast to donepezil (96%) (Nordberg 
and Svensson 1999; Farlow 2001; Bentué-Ferrer et al 2003; 
Farmow 2003; Giacobini 2006). In animals, donepezil is found 
unchanged in brain, and no metabolites are detected in the ner-
vous tissue. In plasma, urine, and bile, most donepezil metabolites 
are O-glucuronides (Matsui et al 1999). In healthy volunteers, 
donepezil is hepatically metabolized and the predominant route 
for the elimination of both parent drug and its metabolites is renal, 
as 79% of the recovered dose was found in the urine with the 
remining 21% found in feces. Moreover, the parent compound is 
the predominant elimination product in urine. The major metabo-
lites of donepezil include M1 and M2 (via O-dealkylation and 
hydroxylation), M11 and M12 (via glucuronidation of M1 and 
M2, respectively), M4 (via hydrolysis) and M6 (via N-oxidation) 
(Tiseo et al 1998f). 
After 14 days administration of donepezil, the cerebral 
acetylcholine level is increased by 35% and the AChE activity 
is decreased by 66% and 32% in rat brain and blood, respec-
tively. No changes are detected in choline acetyltransferase 
activity, or the levels of vesicular acetylcholine transporter, 
choline transporter, or muscarinic receptors. The expression 
of various cholinergic genes is not affected by donepezil. 
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synaptic cleft of the hippocampus mostly through AChE 
inhibition (Kosasa et al 1999) and produces a dose-dependent 
increase in hippocampal theta rhythm amplitude elicited by 
stimulation of the brainstem reticular formation (Kinney et al 
1999). AChE activity in human blood shows 60%–97% and 
43%–89% of pre-exposed level after 1 and 3 days of donepe-
zil administration at a daily dose of 5 mg, respectively (Haug 
et al 2005). The current doses of donepezil at the clinical 
setting are 5 and 10 mg/day. Above 10 mg, AChE inhibition 
is assumed to reach a plateau (Jann et al 2002). 
It is likely that the modest (and variable) therapeutic 
effects of AChEIs are related to their pharmacological 
properties and individual capacity to inhibit AChE activity 
in AD brains. Rakonczay (2003) compared the effects of 8 
AChEIs on AChE and BuChE activity in normal human brain 
cortex. The most selective AChEIs, in decreasing order were: 
TAK-147, donepezil, and galantamine. For BuChE, the most 
speciﬁ  c was rivastigmine; however, none of these AChEIs 
was absolutely speciﬁ  c for AChE or BuChE. Among these 
inhibitors, tacrine, bis-tacrine, TAK-147, metrifonate, and 
galantamine inhibited both the G1 and G4 AChE forms 
equally well (Rakonczay 2003).
The cognitive effects of AChEIs have been studied under 
different paradigms. The most frequent experiments have 
been performed in animals with cholinergic deﬁ  cits or with 
lesions of the nucleus basalis of Meynert, as well as in animal 
models of AD and transgenic animals. 
Donepezil can also act on targets other than cholinester-
ases in the brain. Among possible indirect actions of AChEIs 
to protect AD neurons, several options have been postulated. 
In dissociated hippocampal neurons, donepezil reversibly 
inhibits voltage-activated Na+ currents, and delays rectiﬁ  er 
K+ current and fast transient K+ current. The inhibition of 
donepezil on rectiﬁ  er K+ currents is voltage-dependent, 
whereas that on fast transient currents is voltage-independent. 
The blocking effects of donepezil on the voltage-gated ion 
channels are unlikely to contribute to its clinical effects in 
AD (Yu and Hu 2005). 
Donepezil up-regulates nicotinic receptors in cortical 
neurons, this probably contributing to enhance neuropro-
tection (Kume et al 2005). It has also been suggested that 
AChEIs might promote non-amyloidogenic pathways of 
APP processing by stimulation of α-secretase mediated 
through protein kinase C (PKC) (Pakaski et al 2001). In 
the transgenic Tg2576 mouse model of AD, which exhibits 
age-dependent β-amyloid deposition in the brain as well 
as abnormalities in the sleep-wakefulness cycle probably 
due to a cholinergic deﬁ  cit, the wake-promoting efﬁ  cacy of 
donepezil is lower in plaque-bearing Tg2576 mice than in 
controls (Wisor et al 2005). In AD cases, donepezil increases 
the percentage of REM (rapid eye movements) sleep to total 
sleep time, improving sleep efﬁ  ciency and shortening sleep 
latency (Mizuno et al 2004; Moraes et al 2006). In healthy 
volunteers, donepezil speciﬁ  cally enhances the duration of 
REM sleep (% sleep period time) and the number of REMs 
(Nissen et al 2005). The activation of the visual association 
cortex during REM sleep by donepezil might be responsible 
for the development of abnormal dreams and nightmares in 
AD (Singer et al 2005). 
The inﬂ  uence of AChEIs on APP processing and inhi-
bition of β-amyloid formation, at least in the case of some 
AChEIs (eg, phenserine), does not appear to be associated 
with cholinesterase inhibition but with a novel mechanism 
regulating translation of APP mRNA by a putative inter-
leukin-1 or TGF-β responsive element which has been pro-
posed as a target for drug development (Shaw et al 2001). 
Donepezil and other AChE noncovalent inhibitors are able 
to inhibit AChE-induced β-amyloid aggregation (Tumiatti 
et al 2004). AChEIs may also protect against vascular dam-
age and amyloid angiopathy. In mild–moderate AD patients, 
increased levels of markers of endothelial dysfunction, such 
as thrombomodulin and sE-selectin have been observed. 
After treatment with AChEIs for 1 month, the levels of both 
parameters are markedly reduced, with values approaching 
normal ranges (Borroni et al 2005). In the Tg2576-transgenic 
mouse model in which, at 9–10 months of age, Tg+ mice de-
velop amyloid plaques and impairments on paradigms related 
to learning and memory as compared to transgene-negative 
(Tg-) mice, physostigmine and donepezil improve deﬁ  cits 
in contextual and cued memory in Tg+, but neither drug 
alter the deposition of amyloid plaques (Dong et al 2005). 
In contrast, donepezil protects against the neurotoxic effects 
induced by β-amyloid(1-40) in primary cultures of rat septal 
neurons (Kimura et al 2005). In another transgenic model 
of AD, the AD11 anti-nerve growth factor (anti-NGF) mice, 
oral administration of ganstigmine (CHF2819) and donepezil 
reverses the cholinergic and behavioral deﬁ  cit in AD11 mice 
but not the amyloid and phosphotau accumulation, uncover-
ing different mechanisms leading to neurodegeneration in 
AD11 mice (Capsoni et al 2004). 
Probably via cholinergic modulation at the hypothalamic 
level, donepezil is able to reverse the age-related down-regula-
tion of the GH/IGF-1 axis in elderly males in basal conditions 
and after GHRH stimulation. GHRH-induced GH response 
is magniﬁ  ed by more than 50% after treatment with done-
pezil in healthy elderly subjects (Obermayr et al 2005). The Neuropsychiatric Disease and Treatment 2007:3(3) 313
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enhancement of the somatotropinergic sistem (GRF-GH-IGF 
axis) associated with donepezil treatment might contribute to 
activate GRF/GH-related neurotrophic mechanisms (Cacabe-
los et al 1988a, b). AChEIs also inﬂ  uence pro-inﬂ  ammatory 
cytokines released from peripheral blood mononuclear cells, 
increasing oncostatin M, IL-1β, and IL-6 levels in AD patients 
after treatment (Reale et al 2005). 
Glutamate-related excitotoxicity is an additional deleteri-
ous mechanism secondarily contributing to AD neuropathol-
ogy (Cacabelos et al 1999). The neuroprotective properties of 
AChEIs on glutamate-induced excitotoxicity were investigated 
in primary cultured cerebellar granule neurons. Exposure of 
neurons to glutamate results in neuronal apoptosis. In this 
model, bis(7)-tacrine, a novel dimeric AChEI markedly reduc-
es glutamate-induced apoptosis in a time- and dose-dependent 
manner; however, donepezil and other conventional AChEIs 
do not show any effect (Li et al 2005). Donepezil blocks the 
responses of recombinant NMDA receptors expressed in 
Xenopus oocytes. The blockade is voltage-dependent, sug-
gesting a channel blocker mechanism of action which is not 
competitive at either the L-glutamate or glycine binding sites. 
The low potency of donepezil indicates that NMDA receptor 
blockade does not contribute to its therapeutic effect in AD; 
however, donepezil binds to the sigma1 receptor with high 
afﬁ  nity and shows antidepressant-like activity in the mouse 
forced-swimming test as does the sigma1 receptor agonist 
igmesine. All AChEIs attenuate dizocilpine-induced learning 
impairments, but only the donepezil and igmesine effects are 
blocked by BD1047 or the antisense treatment, suggesting that 
donepezil behaves as an effective sigma1 receptor agonist and 
that interaction with sigma1 protein, but not NMDA receptor, 
might be involved in the pharmacological activity of donepezil 
(Maurice et al 2006). Other studies indicate that donepezil has 
a neuroprotective effect against oxygene-glucose deprivation 
injury and glutamate toxicity in cultured cortical neurons, 
and that this neuroprotection may be partially mediated by 
inhibition of the increase of intracellular calcium concentration 
(Akasofu et al 2006).  
Donepezil inﬂ  uences cells viability and proliferation 
events in SH-SY5Y human neuroblastoma cells. Short- and 
long-exposure of these cells to donepezil induced a concen-
tration-dependent inhibition of cell proliferation unrelated 
to muscarinic or nicotinic receptor blockade or apoptosis. 
Donepezil reduces the number of cells in the S-G2/M 
phases of the cell cycle, increases the G0/G1 population, 
and reduces the expression of two cyclins of the G1/S and 
G2/M transitions, cyclin E and cyclin B, in parallel with 
an increase in the expression of the cell cycle inhibitor p21 
(Sortino et al 2004). Using the same in vitro model, others 
have reported that galantamine, donepezil, and rivastigmine 
afford neuroprotection through a mechanism that is likely 
unrelated to AChE inhibition, suggesting that at least done-
pezil and galantamine, but not rivastigmine, may exert their 
potential neuroproptective effects via α7 nicotinic receptors 
and the PI3K-Akt pathway (Arias et al 2005). In addition, 
donepezil increases action potential-dependent dopamine 
release (Zhang et al 2004) and modulates nicotinic receptors 
of substantia nigra dopaminergic neurons (Di Angelantonio 
et al 2004). 
Donepezil in Alzheimer’s disease
Most clinical trials with donepezil in AD during the past 10 
years have been performed in patients with mild-to-moderate 
dementia (mAD) (Rogers et al 1996, 1998a, 1998b; Burns 
et al 1999; Homma et al 2000; Doody et al 2001a, b; Mohs 
et al 2001; Winblad et al 2001) (Table 2), and a small num-
ber of studies have been carried out in severe cases of AD 
(sAD) (Feldman et al 2001; Bullock et al 2005; Winblad et al 
2006a) (Table 2). More than 10,000 patients recruited from 
26 different countries have been included in major clinical 
trials with AChEIs (24–30 weeks’ duration) during the past 
decade (Giacobini 2006). The typical outcome measures in 
most trials include psychometric assessment, behavior and 
function with different scales. Although the differences in 
the design of clinical trials is obvious, in patients treated 
with donepezil the differences with placebo range from 
0.7–1.2 to 2.8–4.6 points in the ADAS-Cog (Giacobini 
2006; Whitehead et al 2004). Despite this optimistic view 
resulting from the observation of selected trials (Table 2), 
many other studies and meta-analyses (Glegg et al 2001; 
Lanctôt et al 2003; Kaduszkiewicz et al 2005; Loveman et al 
2006; Birks 2006; Birks et al 2006) indicate that AChEIs in 
general and donepezil in particular are of poor efﬁ  cacy in 
AD. In 16 trials with 5159 treated patients (placebo = 2795 
patients) the pooled mean proportion of global responders 
to AChEIs in excess of that of placebo was 9%. The rate of 
adverse events, dropout for any reason and dropout because 
of adverse events were also higher among patients receiv-
ing AChEIs than among those receiving placebo, with an 
excess proportion of 7%–8% (Lanctôt et al 2003). In this 
meta-analysis, including 8 trials with donepezil, 2 trials with 
rivastigmine and 5 trials with galantamine, the cognitive 
response was positive in 23%–35% of patients treated with 
donepezil, in 30% of patients treated with rivastigmine, and 
in 20-32% of patients treated with galantamine. The dropout 
rate was 20%–60% due to adverse events (Lanctôt et al 2003).  Neuropsychiatric Disease and Treatment 2007:3(3) 314
Cacabelos
In a meta-analysis including 22 trials published from 1989 to 
2004, 12 of 14 studies showed an improvement of 1.5–3.9 
points in the ADAS-Cog; however, because of ﬂ  awed methods 
and small clinical beneﬁ  ts, the German evaluators established 
that the scientiﬁ  c basis for recommendations of AChEIs in AD 
was questionable (Kaduszkiewicz et al 2005). In a 10-study 
meta-analysis of donepezil in AD and two-study combined 
analysis of donepezil in vascular dementia (VD), an Irish group 
concluded that although there are differences between AD and 
VD patients in comorbid conditions and concomitant medica-
tions, donepezil is effective and well tolerated in both types of 
dementia (Passmore et al 2005). In the AD2000 clinical trial 
of Courtney et al (2004), no signiﬁ  cant beneﬁ  ts were seen 
with donepezil compared with placebo in institutionalization 
or progression of disability. Similarly, no signiﬁ  cant differ-
ences were seen between donepezil and placebo in behavioral 
and psychological symptoms, carer psychopathology, formal 
care costs, unpaid caregiver time, adverse events or deaths, or 
between 5 mg and 10 mg donepezil (Courtney et al 2004). In 
a critical appraisal of the AD2000 study, the ﬁ  rst long-term 
RCT not sponsored by the pharmaceutical industry, a German 
group led by Kaiser et al (2005) concluded that the widespread 
use of AChEIs in AD is not supported by current evidence, 
and that long-term-randomized controlled trials focusing on 
patient-relevant outcomes instead of cognitive scores are 
urgently needed (Kaiser et al 2005). 
Recent studies in early-stage AD suggest signiﬁ  cant 
treatment beneﬁ  ts of donepezil, supporting the initiation 
of therapy early in the disease course to improve daily 
cognitive functioning (Seltzer et al 2004). During the past 
decade more than 100 papers dealt with the use of AChEIs 
or memantine in severe AD (sAD), but only a few studies 
provide evidence in favor of a positive therapeutic interven-
tion with donepezil in sAD (Feldman et al 2001, 2003, 2005; 
Bullock et al 2005; Forchetti 2005; Winblad et al 2006a). 
In the international literature there are 13 articles related to 
donepezil in sAD, but only 3 fulﬁ  l strict criteria for further 
consideration (Rawls 2005) 
In one study, to evaluate efﬁ  cacy and safety of donepezil 
in sAD, Feldman et al (2001) found that donepezil had sig-
niﬁ  cant beneﬁ  ts over placebo on global, cognitive, functional, 
and behavioral measures in patients with sAD (Feldman 
et al 2001, 2005). In another study of Feldman et al (2003), 
donepezil demonstrated a signiﬁ  cantly slower decline than 
placebo in instrumental and basic ADLs in patients with 
m/sAD. Bullock et al (2005) found similar effects of done-
pezil and rivastigmine on cognition and behavior in m/sAD. 
Winblad et al (2006a) have studied 248 patients with severe 
AD (sAD) (MMSE score: 1–10) living in nursing homes of 
Sweden for 6 months. The patients (n = 128) received 5 mg/
day of donepezil for 30 days and then 10 mg/day thereafter. 
The primary end points in this study were change from base-
line to month 6 in the severe impairment battery (SIB) and 
modiﬁ  ed Alzheimer’s Disease Cooperative Study activities 
of daily living inventory for severe AD (ADCS-AD-severe). 
Under this protocol, 95 patients assigned donepezil and 99 
patients assigned placebo (n = 120) completed the study. AD 
patients treated with donepezil improved more in SIB scores 
and declined less in ADCS-ADL-severe scores after 6 months 
of treatment compared with baseline than did the patients 
enrolled in the placebo group (Winblad et al 2006a).
To evaluate the representation of frail older adults in ran-
domized controlled trials (RCTs), and to assess consequences 
of under representation by analyzing drug discontinuation 
rates, Gill et al (2004) studied a cohort of older adults newly 
dispensed donepezil (n = 6424) in Ontario between Septem-
ber 2001 and March 2002, and compared patients dispensed 
donepezil to clinical trials subjects. In this interesting study, 
between 51% and 78% of the Ontario cohort would have been 
ineligible for RCT enrolment. Patients dispensed donepezil 
were older (>80 years) and more likely to be in long-term 
care than RCT subjects. Overall, 27.8% of the Ontario cohort 
discontinued donepezil within 7 months of initial prescrip-
tion, and the discontinuation rates were signiﬁ  cantly higher 
for patients with a history of obstructive lung disease, active 
cardiovascular disease, or parkinsonism (Gill et al 2004). 
It would be highly recommendable that outcome mea-
sures of efﬁ  cacy in the long-term incorporate speciﬁ  c AD-
related biomarkers (eg, serum markers, cerebro-spinal ﬂ  uid 
[CSF] markers, neuroimaging biomarkers [MRI, fMRI, 
PET, SPECT], brain atrophy rate, brain perfusion, optical 
topography) (McMahon et al 2000; Jagust 2004; Dickerson 
and Sperling 2005). In this regard, PET studies have dem-
onstrated that donepezil-induced inhibition of cortical AChE 
is modest (19%–24%) in patients with mAD. In the brain of 
AD patients assessed with an AChE tracer by PET scanning, 
treatment with donepezil for 3 months reduced AChE activ-
ity by 39% in the frontal cortex, 29% in the temporal cortex, 
and 28% in the parietal cortex (Kaasinen et al 2002). The 
degree of cortical AChE inhibition correlates with changes 
in excutive and attentional functions (Bohnen et al 2005). 
Long-term treatment with donepezil can lead to a lesser de-
terioration in qEEG, paralleling a milder neuropsychological 
decline (Rodríguez et al 2002), with reduction of slow-wave 
activity in frontal and temporo-parietal areas (Kogan et al 
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after donepezil treatment (Werber et al 2001). By using the 
rate of hippocampal atrophy as a surrogate marker of disease 
progression, Hashimoto et al (2005) found that treatment with 
donepezil slows the progression of hippocampal atrophy in 
AD (mean annual rate of hippocampal volume loss: 3.82%) 
as compared with untreated patients (5.04%). Smaller hip-
pocampal volume and inward variation of the lateral and 
inferomedial portions of the hippocampal surface were cor-
related with a poorer response to donepezil therapy in dementia 
(Csernansky et al 2005). AD patients who show more severe 
cholinergic dysfunction and less severe structural damage of 
the hippocampus and parahippocampus are likely to respond 
to donepezil treatment (Tanaka et al 2003a). Atrophy of the 
substantia innominata was more pronounced in transiently 
and continuously responding groups than in non-responders. 
Logistic regression analysis revealed that the overall discrimi-
nation rate with the thickness of the substantia innominata was 
70% between responders and non-responders, suggesting that 
atrophy of the substantia innominata on MRI helps to predict 
response to donepezil treatment in AD (Tanaka et al 2003b). 
Krishnan et al (2003) have found that donepezil treated pa-
tients had signiﬁ  cantly smaller mean decreases in total and 
right hippocampal volumes and a smaller, nearly signiﬁ  cant 
mean decrease in left hippocampal volume, compared with 
the placebo-treated patients. Other studies revealed that the 
diversity of clinical responses to donepezil therapy in AD is 
associated with regional cerebral blood ﬂ  ow (rCBF) changes, 
mainly in the frontal lobe (Shimizu et al 2006). Furthermore, 
there is a parallelism between cognitive improvement and 
increase in brain M1 muscarinic receptor binding after treat-
ment with donepezil in AD (Kemp et al 2003). AChE activity 
also decreases in the CSF of patients treated with donepezil, 
but changes in other biomarkers, such as BuChE activity, β-
amyloid (1–42), tau and phosphorylated tau proteins are not 
affected by donepezil treatment (Parnetti et al 2002). 
In summary, it appears that donepezil is beneﬁ  cial (in 
a dose-dependent manner) when assessed using global and 
cognitive outcome measures in AD; however, by ﬁ  nding the 
mean effect sizes of the treatment on the outcome measures 
of cognition from 8 empirical studies, it was determined that 
neither donepezil nor other AChEIs were greatly efﬁ  cacious 
(Harry and Zakzanis 2005). Over 770 million days of patient 
use and an extensive publication database demonstrate that 
donepezil has a good tolerability and safety proﬁ  le (Jackson 
et al 2004). The use of AChEIs in AD is currently appraised 
by the National Institute for Clinical Evidence (NICE). In 
a recent review providing the latest, best quality evidence 
of the effects of AChEIs on cognition, quality of life and 
adverse events in people with mild to moderately-severe AD 
(m/sAD), Takeda et al (2006) stated (on a systemtic review 
of 26 RCTs) that AChEIs can delay cognitive impairment in 
m/sAD for at least 6 months duration; however, results from 
head to head comparisons are limited by the low number of 
studies and the study quality. The Cochrane Database Re-
viewers conclude that people with mAD or sAD treated for 
periods of 12, 24, or 52 weeks with donepezil experienced 
beneﬁ  ts in cognitive function, activities of the daily living 
and behavior. Study clinicians rated global clinical state more 
positively in treated patients, and measured less decline in 
measures of global disease severity (Birks and Harvey 2006). 
In general terms, there is not robust support for any AChEI 
because the treatment effects are small and are not always 
apparent in practice (Birks and Harvey 2006; Takeda et al 
2006). Donepezil treatment may be associated with reduced 
mortality in nursing home residents with dementia (Gasper 
et al 2005) and with delayed nursing home placement 
(Geldmacher et al 2003), although some authors denied that 
donepezil was able to reduced the rate of institutionaliza-
tion or disability in mAD (Courtney et al 2004; Standridge 
2004). The meta-analysis of caregiver-speciﬁ  c outcomes 
in antidementia clinical trials revealed that AChEIs have a 
small beneﬁ  cial effect on burden and active time use among 
caregivers of persons with AD (Lingler et al 2005). 
Mild cognitive impairment
Mild cognitive impairment (MCI) is the postulated transi-
tional state between the cognitive changes of normal aging 
and early AD (Petersen et al 1999, 2005). The rate of progres-
sion to clinically diagnosable AD is 10%–15%/year among 
persons who meet the criteria for the amnestic form of MCI, 
in contrast to a rate of 1–2%/year among normal elderly 
persons (Petersen et al 1999). This is a clinical concept and 
instrumental aid invented to substitute the lack of accurate 
biological markers able to predict the risk of suffering AD. 
Despite its questionable value, it is important to keep in mind 
that neurodegeneration starts many years before the onset of 
the disease (Cacabelos et al 2005). It is very likely that AD 
neurons begin their deceasing process 20–40 years prior to 
the appearance of the ﬁ  rst symptoms (eg, memory deﬁ  cit, 
behavioral changes, functional decline, subtle praxis-related 
psychomotor alterations). In some patients with a speciﬁ  c 
genetic proﬁ  le, it is possible to detect, by means of sensitive 
brain imaging techniques, a progressive brain dysfunction 
after the age of 30 years (Cacabelos 2003, 2005b). In this 
regard, it is clear that an early therapeutic intervention could 
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of a premature neuronal death or delaying the onset of the 
disease for several years. AChEIs have been proposed as 
feasible candidate drugs for the treatment of MCI (Stirling 
Meyer et al 2002; Salloway et al 2003; Gauthier 2005). 
Few studies have been performed with donepezil in MCI 
(Jelic et al 2005). In a double-blind, placebo-controlled, 
multicenter trial in US with 270 cases, a mild beneﬁ  t in 
cognitive function has been reported (Salloway et al 2004). 
A Chinese group has performed a clinical trial with donepezil 
(2.5 mg/day for 3 months) in patients with amnestic MCI and 
found a signiﬁ  cant improvement in cognitive performance as 
well as changes in the hippocampus as assessed by magnetic 
resonance spectroscopy (MRS) (Wang et al 2004). 
In a recent study, Petersen et al (2005) evaluated 769 
subjects with the amnestic subtype of MCI in a randomized, 
double-blind study with donepezil (10 mg/day) or vitamin E 
(2000 IU/day) for 3 years. The overall rate of progression 
from MCI to AD was 16%/year (212 patients evolved into 
the AD condition). As compared with the placebo group, 
there were no signiﬁ  cant differences in the probability of 
progression to AD in the vitamin E group or the donepezil 
group during the 3 years of treatment. The donepezil group 
had a reduced likelihood of progression to AD during the ﬁ  rst 
12 months of the study, with better results among APOE-4 
carriers (Petersen et al 2005). 
The proposed beneﬁ  t of AChEI therapy as a preventive 
strategy in MCI or as a regular option for people requesting 
some medication for memory improvement is far from clear 
and probably poses some underestimated dangers, despite the 
optimistic position of some authors (Jelic et al 2005). It has 
been observed that neuropsychological test performance de-
teriorates in healthy elderly volunteers receiving donepezil for 
2 weeks; worsening is signiﬁ  cant on tests of speed, attention, 
and short-term memory as compared with the placebo group, 
suggesting a perturbation of an already optimized cholinergic 
system in healthy subjects (Beglinger et al 2005). If the rate of 
conversion form MCI into AD is about 10%–15% per year, it 
is probably irresponsible to sacriﬁ  ce 80% MCI cases to pyr-
rhically protect only 10% assuming that AChEIs in healthy 
subjects may induce undesirable cognitive effects. 
The postulated long-lasting effects of AChEIs for 1–5 
years (Doody et al 2001b; Bullock and Dengiz 2005; Giaco-
bini 2006) were never clearly documented in well-controlled 
trials. In a recent study, Winblad et al (2006b) provide some 
support to the long-lasting efﬁ  cacy and safety of donepezil 
after 3 years of treatment. In a cohort of 286 patients, there 
was a trend for patients receiving continuous therapy to have 
less global deterioration on the Gottfries-Brane-Steen scale 
than those who had delayed treatment. Small but statistically 
signiﬁ  cant differences between the groups were observed 
for the secondary measures of cognitive function (MMSE 
scores) and cognitive and functional abilities (GDS) in favor 
of continuous donepezil therapy (Winblad et al 2006b).
On a pathogenic basis, there is no evidence that AChEIs 
protect neurons against AD-related premature death. It might 
occur – as demonstrated with multifactorial therapies in AD 
(Cacabelos et al 2004c) – that cognitive enhancement induced 
by AChEI administration is the result of forcing surviving 
neurons to overwork for a period of time after which neu-
rons become exhausted with the subsequent acceleration of 
their metabolic decline. This phenomenon has been demon-
strated after administration of a combination therapy with 
CDP-choline, piracetam, and metabolic supplementation 
(Cacabelos et al 2004c). Under this therapeutic protocol, AD 
patients clearly improved for the ﬁ  rst 9 months of treatment, 
and a progressive decline in therapeutic efﬁ  cacy has been 
observed thereafter (Cacabelos et al 2004c; Cacabelos 2003, 
2005a, b). The study of Petersen et al (2005) might be a good 
paradigm to illustrate the same phenomenon with donepezil 
in MCI patients who showed a positive response during the 
ﬁ  rst year of treatment and no effect after 3 years. Taking 
into account these observations, we should be very cautious 
with the administration of pharmaceuticals (as a preventive 
strategy) to patients with MCI until a clear long-lasting ef-
ﬁ  cacy of the therapeutic options can be demonstrated. This 
is especially important when some studies reveal that chronic 
administration of AChEIs (eg, galantamine) may even in-
crease mortality (Scheltens et al 2004; Kirshner 2005). 
Combination therapies
Combination drug therapy is the standard of care for treat-
ing many neuropsychiatric disorders and other medical 
conditions (eg, cardiovascular disease, hypertension, cancer, 
AIDS, diabetes). For the past 20 years, the pharmaceutical 
industry and the medical community have made a show of 
reluctance to treat AD with a combination therapy, but in fact 
most patients with dementia have been receiving an average 
of 6–9 different drugs per day in an attempt to control the 
multifaceted expressions of dementia. Multifactorial therapy, 
combining several types of drugs with potential neuroprotec-
tive effect on the CNS, has been tried in AD and other forms 
of dementia with promising results (Cacabelos et al 2000a b; 
Cacabelos 2002a b; Cacabelos 2003; Cacabelos et al 2004c; 
Cacabelos 2005a, b; Cacabelos et al 2006). Donepezil has 
been given in combination with other substances to patients 
with AD. Probably the best evidence-based combination Neuropsychiatric Disease and Treatment 2007:3(3) 317
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strategy is the addition of memantine to stable donepezil 
therapy in m/sAD (Tariot et al 2004; van Dyck et al 2006). 
This combination was found to beneﬁ  t cognition, behavior, 
and activities of daily living. It appears that memantine 
in combination with donepezil is signiﬁ  cantly better than 
donepezil alone in the management of behavioral symptoms 
(Tariot et al 2004; Xiong and Doraiswamy 2005; Doody 
2005). Combination therapy with donepezil and memantine 
in healthy subjects did not show any signiﬁ  cant alteration 
in pharmacokinetic or pharmacodynamic parameters of 
both drugs, suggesting that donepezil and memantine may 
be safely and effectively used in combination (Periclou et al 
2004). According to basic studies using the whole-cell patch-
clamp technique with multipolar neurons, the combination 
of donepezil and memantine might be a contradiction since 
donepezil potentiates NMDA currents (Moriguchi et al 
2005) and memantine acts as a partial NMDA antagonist 
(Cacabelos et al 1999).
Combination therapy of donepezil (5 mg/day) with ginkgo 
biloba (90 mg/day) for 30 days did not show any signiﬁ  cant 
difference in cognitive performance, pharmacokinetics and 
pharmacodynamics of donepezil, indicating that ginkgo 
supplementation does not have major impact on donepezil 
therapy (Yasui-Furukori et al 2004). Donepezil has also been 
given in combination with acetyl-L-carnitine (ALC) in AD. 
The addition of ALC to donepezil increased the response rate 
from 38% (AChEI alone) to 50% (AChEI + ALC) (Bianchetti 
et al 2003). Initial data resulting from combination studies of 
donepezil and vitamin E indicated that this long-term combi-
nation might be beneﬁ  cial for AD (Klatte et al 2003). 
Donepezil plus sertraline did not show any advantage 
over donepezil alone in AD, although the combination 
appeared to be beneﬁ  cial in a subgroup of patients with 
moderate-to-severe behavioral and psychological symptoms 
(Finkel et al 2004). In patients with psychotic symptoms and 
lack of improvement of their delusions/hallucinations during 
perphenazine treatment, donepezil may reduce psychotic 
symptoms, suggesting that donepezil augmentation of neu-
roleptics (risperidone, olanzapine, quetiapine) may be appro-
priate for those patients for whom neuroleptic monotherapy 
either does not lead to symptom remission or is associated 
with intolerable side-effects (Bergman et al 2003). In some 
cases the combination of donepezil and neuroleptics may 
exacerbate extrapyramidal side-effects (Liu et al 2002). In 
general, combination therapy tends to show better results 
than monotherapy with one AChEI or any other single drug 
for dementia (Cacabelos 2002a, b; Cacabelos et al 2004c; 
Cacabelos 2005a, b). Similar results can be seen in animal 
models when donepezil is given in combination with other 
compounds (Sonkusare et al 2005).  
Comparative studies
Comparative studies with different AChEIs did not show 
any signiﬁ  cant difference or traces of superiority among 
them in AD patients (Wilkinson et al 2002; Ritchie et al 
2004; Aguglia et al 2004; Bullock et al 2005; Harry and 
Zakzanis 2005). In independent studies, there are apparent 
differences in ADAS-Cog changes, improvement rate, drop-
outs, and incidence of side-effects among different classes of 
AChEIs; however, since the clinical protocols vary from one 
study to another, these results are not comparable and unreli-
able. In a number of studies analysed by Giacobini (2006) 
comparing 7 AChEIs, the ADAS-Cog variation vs placebo 
(AD/P) was 4.0–5.3/0.8–2.8 with tacrine, 4.7/1.83 with ep-
tastigmine, 2.8–4.6/0.7–1.2 with donepezil, 1.9–4.9/0.7–1.2 
with rivastigmine, 2.8–3.2/0.5–0.75 with metrifonate, and 
3.1–3.9/1.73 with galantamine. About 30%–50% of pa-
tients improved with tacrine, 40%–58% with donepezil, 
25%–37% with rivastigmine, 35%–40% with metrifonate, 
and 10%–23% with galantamine. The drop-out rate was 
55%–73% in patients treated with tacrine, 35% with eptastig-
mine, 5%–13% with donepezil, 15%–36% with rivastigmine, 
2%–28% with metrifonate, and 10%–13% with galantamine. 
Side-effects were more prevalent in patients treated with 
tacrine (405–58%) than with the other AChEIs (donepezil, 
6%–13%; rivastigmine, 15%–28%; metrifonate, 2%–12%; 
galantamine, 13%–16%) (Giacobini 2006). In clinical terms, 
according to Birks (2006), despite the slight variations in the 
mechanism of action of donepezil, rivastigmine, and galan-
tamine, there is no evidence of any substantial differences 
between them with respect to efﬁ  cacy; even though there 
appears to be less adverse effects associated with donepezil 
compared with rivastigmine (Birks 2006).
Effects on behavioral symptoms 
and functional deﬁ  cits
Dementia is clinically characterized by memory disorders, 
behavioral changes, and progressive functional decline. 
The estimated prevalence of psychiatric symptoms in AD 
accounts for 40%–60% of the cases (Cacabelos et al 1996; 
Cacabelos et al 1997). In cross-sectional studies it has been 
reported that several psychiatric symptoms are associated 
with lower total MMSE scores and overall cognitive dete-
rioration. Psychotic symptoms, especially delusions, hal-
lucinations and misidentiﬁ  cations, are positively correlated 
with aggressive behavior and institutionalization. Agitation Neuropsychiatric Disease and Treatment 2007:3(3) 318
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and wandering are also associated with rapid cognitive de-
cline in dementia. In general, psychotic symptoms parallel 
an accelerated cognitive deterioration, partially induced by 
psychotropic drugs in some cases or by many other classes 
of drugs currently used by patients in geriatric long-term 
settings (Arinzon et al 2006). In other cases, behavioral 
changes do not seem to be associated with exogenous factors 
and might be intrinsic to cortical atrophy and selective brain 
damage in dementia. The prevalence of psychotic symptoms 
in AD ranges from 15% to 50%, constituting a very common 
problem which is not always reduced by conventional anti-
psychotic or antianxiety drugs. In addition, antypsychotics 
may increase the risk of cerebrovascular accidents and also 
contribute to cortical atrophy after years of chronic treatment 
(Cacabelos et al 1996, 1997; Gill et al 2005). Furthermore, 
behavioral symptoms in AD signiﬁ  cantly increase direct costs 
of care (US$10,670–16,141 higher annual costs in high-NPI 
as compared with low-NPI) (Murman et al 2002). Several 
studies with AChEIs indicate that these compounds may exert 
a beneﬁ  cial effect on some neuropsychiatric symptoms such 
as delusions, hallucinations, apathy, psychomotor agitation, 
depression and anxiety (Levy et al 1999; Trinh et al 2003). 
It is likely that AChEIs interact with atypical neuroleptics to 
synergistically increase the antipsychotic effect, this allowing 
a potential reduction in the dose of neuroleptics (Weiser et al 
2002). What has to be demonstrated is that this pharmaco-
dynamic interaction is common to all AChEIs, because it 
can not be excluded that some AChEIs may also precipitate 
psychotic symptoms and exacerbate extrapyramidal side-
effects when given in combination with neuroleptics (eg, 
donepezil + risperidone) (Liu et al 2002). 
Several papers have documented the parallel beneﬁ  cial 
effects of donepezil on cognition and behavioral symptoms 
in AD (Matthews et al 2000; Tariot et al 2001; Paleacu et al 
2002; Gauthier et al 2002a; Gauthier et al 2002b; Holmes 
et al 2004) (Table 2). In clinical trials, sleep problems have 
been identiﬁ  ed as side-effects of donepezil. Poor sleep quality 
can exacerbate behavioral problems among patients and add 
to the burden experienced by caregivers. In a community-
based study, the use of hypnotics was higher in donepezil 
users (9.78%) compared with non-users (3.93%) (Stahl et al 
2003). Behavioral symptoms are a major problem in AD 
and, assuming that most psychotropic drugs contribute to 
deteriorate cognition and psychomotor function, as well as 
cerebrovascular function (Maguire 2000; Gill et al 2005), 
AChEIs represent an option to be explored in more detail as 
a monotherapy or in combination with other psychotropic 
agents at low doses (Barak et al 2001; Masterman 2004). 
Donepezil in vascular dementia
Cerebrovascular dysfunction is a common ﬁ  nding in demen-
tia; and mixed dementia (MXD) (degenerative + vascular) 
is the most frequent form of dementia in older patients 
(> 75–80 years) (Cacabelos 2003; Cacabelos et al 2003, 
2004a, b). Diverse vascular risk factors (cardiovascular 
disorders, hypertension, hypotension, hypercholesterolemia, 
dyslipemia, atherosclerosis, diabetes) accumulate in patients 
with dementia and are at the basis of the pathogenic mecha-
nisms leading to vascular dementia (VD) (Cacabelos 2003; 
Cacabelos et al 2003; Cacabelos 2004a). 
Studies with donepezil (Black et al 2003; Wilkinson et al 
2003), and other AChEIs (Erkinjuntti et al 2002), have shown 
modest effects in VD. Improvements have been observed 
in cognition, behavior, and activities of daily living in VD 
patients treated with donepezil in a similar fashion to those 
detected in AD (Erkinjuntti et al 2002; Black et al 2003; 
Goldsmith and Scott 2003; Wilkinson et al 2003; Blasko 
et al 2004; Erkinjuntti et al 2004; Roman 2004; Roman 
et al 2005). The combined analysis of 2 identical randomized, 
double-blind, placebo-controlled, 24-week studies involv-
ing 1219 patients enrolled at 109 investigational sites in the 
USA, Europe, Canada, and Australia, revealed that donepezil 
groups showed signiﬁ  cant improvements in cognition, global 
function, and ADLs (Roman et al 2005). In post-marketing 
studies, donepezil in VD (sometimes called AD + cerebro-
vascular disease) patients appears to show similar beneﬁ  ts 
to those observed in AD patients in the areas of cognition, 
global function, and quality of life (Malouf and Birks 2004; 
Schindler 2005). The main features of VD patients included 
in donepezil studies were the following: 68% of patients had 
a history of at least one stroke, and 28% of patients had a 
history of transient ischemic attacks before dementia; 99% 
of cases exhibited cortical and subcortical infarcts; 73% 
of patients had experienced an abrupt onset of cognitive 
symptoms; and vascular risk factors were prominent and 
included hypertension (70%), smoking (62%), and hyper-
cholesterolemia (39%) (Pratt 2005). In general, diagnostic 
criteria, inclusion criteria, autcome measures (psychometric 
and instrumental), and follow-up studies are deﬁ  cient in clini-
cal trials with VD patients; furthermore, many cases with 
minor cerebrovascular damage and vascular risk factors are 
currently included in AD trials and neglected in VD trials 
(Cacabelos et al 2003, 2004a, b).
An important cerebrovascular component is present in 
most AD cases older than 70–75 years of age, and most 
cases of dementia are of the mixed type in older patients 
(> 80 years) who exhibit a clear brain hypoperfusion pattern Neuropsychiatric Disease and Treatment 2007:3(3) 319
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as well as accumulation of vascular risk factors (Cacabelos 
2003, 2004; Cacabelos et al 2003, 2004a, b). Glucose me-
tabolism tends to decline over time in the bilateral precuneus 
and posterior cingulated gyri and in the frontal, temporal and 
parietal cortices of AD patients (Hirono et al 2004). Stud-
ies of regional cerebral blood ﬂ  ow (rCBF) as assessed by 
SPECT revealed that AD patients showed a preserved rCBF 
in the right and left anterior cingulated gyri, right middle 
temporal gyrus, right inferior parietal lobe, and prefrontal 
cortex after 1-year of treatment with donenezil (Nakano 
et al 2001). Signiﬁ  cant rCBF reduction was observed in 
the temporal lobe and occipital-temporal cortex of the left 
hemisphere of untreated patients, whereas no signiﬁ  cant 
change was observed in patients treated with donepezil for 
1 year (Nobili et al 2002). In a small study (n = 10), patients 
with vascular dementia improved their cognitive function 
and the latency of the P300 auditory ERPs after one month 
of treatment with donepezil (Paci et al 2006). In another 
study with 15 VD patients, a marginal effect was observed 
on MMSE scores, with substantial gains on tests of work-
ing memory and delayed recognition memory (Thomas 
et al 2005). According to some Japanese authors, vascular 
lesions and related risk factors may inﬂ  uence responsiveness 
to donepezil in AD. For instance, high HDS-R (Revised-
Hasegawa Dementia Scale), low CDT (Clock Drawing Test) 
scores, low CDR (Clinical Dementia Rating), and the pres-
ence of hypertension and periventricular hyperintensities 
predicted the proﬁ  le of true responders (Fukui and Taguchi 
2005). Others have found that antihypertensive medications 
in AD patients treated with AChEIs are associated with an 
independent improvement on cognition after 40 weeks of 
treatment (Rozzini et al 2005). 
Side-effects and major adverse drug 
reactions (ADRs)
On average, side-effects in donepezil trials account for 
20%–60% of dropouts and are present in 10%–70% of the 
patients depending upon type and severity of the ADRs. Side-
effects and ADRs associated with donepezil can be classiﬁ  ed 
in two main categories: common side-effects, most of them 
observed in clinical trials with AD patients, and unfrequent 
or extraordinary side-effects, seen in especial conditions or 
in small clusters of patients with different pathologies under 
treatment with other concomitant drugs. The most frequent 
ADRs (Table 3) occurring in more than 5% of patients treated 
with donepezil include body events (45%), cardiovascular 
problems (18%), alterations in the digestive system (34%), 
hematic and lymphatic alterations (5%), metabolic and 
nutritional changes (6%), musculoskeletal problems (17%), 
complications in the respiratory system (22%), skin and 
appendages (14%), special senses (5%), urogenital (24%), 
and CNS (52%) (agitation, insomnia, confusion, depres-
sion, anxiety, dizziness, vertigo, headache, restlessness, 
hallucinations) (Bryson and Benﬁ  eld 1997; Rogers 1998; 
Doody 1999; Nordberg and Svensson 1999; Wilkinson 1999; 
Dunn et al 2000; Greenberg et al 2000; Rogers et al 2000; 
Bentué-Ferrer et al 2003; Jackson et al 2004; Courtney et al 
2004; Johannsen et al 2006). Other important side-effects 
observed in patients treated with donepezil include agita-
tion, aggressive and violent behavior in AD and Down’s 
syndrome; extrapyramidal symptoms and tardive dyskinesia 
in schizophrenia and psychotic disorders; catatonia in DLB; 
and a number of rare effects, such as athetosis, Pisa syndrome 
(pleurothonus) (Kwak et al 2000; Miyaoka et al 2001), 
a fulminant chemical hepatitis possibly associated with 
donepezil and sertraline therapy in an 83-year-old woman 
(Verrico et al 2000), purpuric rash in an 82-year-old woman 
receiving long-term treatment with atenolol and doxazosin 
(Bryant et al 1998), hypnopompic hallucinations (Yorston and 
Gray 2000), urinary incontinence (Hashimoto et al 2000), 
extrapyramidal syndrome (Magnuson et al 1998; Carcenac 
et al 2000), seizures (Babic and Zurak 1999), pancreatitis, 
syncope (Greenberg et al 2000), mania (Benazzi 1999; Ja-
cobsen and Comas-Diaz 1999), violent behavior (Bouman 
and Pinner 1998), and some other ADRs in isolated cases 
with different pathologies (Table 3).  
Donepezil may adversely inﬂ  uence cardiovascular au-
tonomic control (McLaren et al 2003). More than 40% of 
elderly subjects susceptible of treatment with AChEIs show 
some kind of cardiac dysfunction. Donepezil reduces mean 
heart rate, especially low (0.04–0.15 Hz) and high (0.15–0.40 
Hz) frequency components of the ECG (1–30 sec modulation 
of heart rate variability) (Masuda and Kawamura 2003). In 
patients receiving donepezil for more than 1 year several 
cases of syncope have been reported. In 31% of the cases, 
no cause of syncope was found; and in 69% of the cases the 
cause of syncope was associated with carotid sinus syndrome, 
complete atrioventricular block, sinus node dysfunction, 
severe orthostatic hypotension and paroxysmal atrial ﬁ  bril-
lation (Bordier et al 2005). 
Another important issue in the prescription of AChEIs 
is the potential interaction of these agents with psychotropic 
drugs and other medications. Drug–drug interactions can 
be observed between donepezil and antidepressants such as 
serotonin uptake inhibitors (sertraline, paroxetine, ﬂ  uoxetine) 
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(risperidone, olanzapine, quetiapine), antihistaminics, and anti-
epileptics. Donepezil can aggravate extrapyramidal symptoms 
when co-administered with atypical antipsychotics (eg, risperi-
done). The cholinergic activity of some histamine H1 receptor 
antagonists or tricyclic antidepressants can be antagonized by 
donepezil. Despite all these theoretical possibilities, most stud-
ies reported to date demonstrate that drug–drug interactions 
with donepezil (memantine, risperidone, sertraline, levodopa, 
thioridazine, theophylline, furosemide, cimetidine, warfarin, 
digoxin, ginkgo biloba, piracetam, CDP-choline, anapsos, 
topiramate) do not show clinical relevance (Tiseo et al 1998a, 
b, c, d; Yasui-Furukori et al 2004; Nagy et al 2004; Okereke 
et al 2004; Periclou et al 2004; Ravic et al 2004; Reyes et al 
2004; Seltzer 2005; Wheeler 2006), except in isolated cases 
(Magnuson et al 1998; Zhao et al 2003). The concurrent 
administration of ketoconazole and donepezil produces no 
change in ketoconazole plasma concentrations, but a statisti-
cally signiﬁ  cant change in donepezil plasma concentrations. 
These changes might be associated with CYP2D6-related en-
zyme interactions (Tiseo et al 1998e). A case of malignant-like 
syndrome due to donepezil and maprotiline has been reported 
(Ohkoshi et al 2003). Another case of malignant syndrome has 
been reported in a 68-year-old Japanse patient with history of 
delusions and hallucination under treatment with bromperidol 
(12 mg) and donepezil (5 mg) (Ueki et al 2001). Donepezil 
may also interact with some anesthetics. It can not be excluded 
that donepezil act on muscle plaque, blocking acetylcholine 
hydrolysis and antagonizing atracurium, since in a 75-year-
old AD patient undergoing left colectomy under general 
anesthesia, after 14 months of treatment with donepezil, suc-
cinylcholine-induced relaxation was markedly prolonged and 
the effect of atracurium besylate was inadequate even at very 
high doses (Sánchez Morillo et al 2003). Suxamethonium and 
donepezil may also be a cause of prolonged paralysis (Crowe 
and Collins 2003). 
Recent ﬁ  ndings indicate that donepezil users may experi-
ence changes in lipid proﬁ  le. Statistically signiﬁ  cant higher 
levels of triglycerides, cholesterol, LDL-cholesterol, and 
VLDL-cholesterol have been found in donepezil users as 
compared with non-users (Adunsky et al 2004). Moreover, 
high cholesterol levels correlated with faster decline at 
1-year follow-up in AD patients on AChEI therapy (Bor-
roni et al 2003). In this regard, it is important to keep in 
mind that alterations in lipid metabolism might represent an 
additional risk factor for dementia and that APOE-related 
cholesterol changes are currently seen in AD (Cacabelos 
2003, 2004; Cacabelos et al 2004a, b). If donepezil-related 
cholesterol alterations are conﬁ  rmed in well-controlled 
trials, in which genotype-related patient stratiﬁ  cation is 
highly recommended, then donepezil should be avoided in 
vulnerable cases. 
Pharmacogenetics
With the advent of recent knowledge on the human genome 
(International Human Genome Sequencing Consortium 2004) 
and the identiﬁ  cation and characterization of AD-related 
genes (Cacabelos et al 2005), as well as novel data regarding 
CYP family genes and other genes whose enzymatic products 
are responsible for drug metabolism in the liver (eg, NATs, 
ABCBs/MDRs, TPMT), it has been convincingly postulated 
that the incorporation of pharmacogenetic and pharmacoge-
nomic procedures in drug development might bring about 
substantial beneﬁ  ts in terms of therapeutics optimization in 
dementia (Cacabelos 2002a, b; Cacabelos 2005a, b) and in 
many other complex disorders, assuming that genetic factors 
are determinant for both premature neuronal death in AD and 
drug metabolism (Cacabelos 2005a, b; Cacabelos et al 2005). 
With pharmacogenetics we can understand how genomic 
factors associated with genes encoding enzymes responsible 
for drug metabolism regulate pharmacokinetics and phar-
macodynamics (mostly safety issues) (Evans and McLeod 
2003; Weinshilboum 2003; Weinshilboum and Wang 2006). 
With pharmacogenomics we can differentiate the speciﬁ  c 
disease-modifying effects of drugs (efﬁ  cacy issues) acting 
on pathogenic mechanisms directly linked to genes whose 
mutations determine alterations in protein synthesis or subse-
quent protein misfolding and aggregation (Cacabelos 2002a, 
b; Nebert and Jorge-Nebert 2002; Cacabelos 2003; Cacabelos 
2005a, b). The capacity of drugs to reverse the effects of the 
activation of pathogenic cascades (phenotype expression) 
regulated by networking genes basically deals with efﬁ  cacy 
issues. The application of these procedures to dementia is a 
very difﬁ  cult task, since dementia is a complex disorder in 
which more than 200 genes might be involved (Cacabelos 
et al 2005). In addition, it is very unlikely that a single drug 
be able to reverse the multifactorial mechanisms associated 
with premature neuronal death in most dementing processes 
with a complex phenotype represented by memory decline, 
behavioral changes, and progressive functional deterioration. 
This clinical picture usually requires the utilization of differ-
ent drugs administered simultaneously, including memory 
enhancers, psychotropics (antidepressants, neuroleptics, 
anxiolytics), anticonvulsants, antiparkinsonians, and also 
other types of drugs of current use in the elderly due to the 
presence of concomitant ailments (eg, hypertension, cardio-
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Although drug effect is a complex phenotype that depends 
on many factors, it is estimated that genetics accounts for 
20%–95% of variability in drug disposition and pharmaco-
dynamics (Weinshilboum 2003). Cholinesterase inhibitors of 
current use in AD, such as donepezil and rivastigmine (and 
tacrine, as well) are metabolized via CYP-related enzymes 
(Table 1). These drugs can interact with many other drugs 
which are substrates, inhibitors or inducers of the cytochrome 
P-450 system, this interaction eliciting liver toxicity and 
other adverse drug reactions (ADRs) (Cacabelos 2005a, b) 
(Tables 1 and 3). Many of these substances are metabolized 
by enzymes known to be genetically variable, including: (a) 
esterases: butyrylcholinesterase, paraoxonase/arylesterase; 
(b) transferases: N-acetyltransferase, sulfotransferase, thiol 
methyltransferase, thiopurine methyltransferase, catechol-
O-methyltransferase, glutathione-S-transferases, UDP-gluc-
uronosyltransferases, glucosyltransferase, histamine methyl-
transferase; (c) reductases: NADPH:quinine oxidoreductase, 
glucose-6-phosphate dehydrogenase; (d) oxidases: alcohol 
dehydrogenase, aldehydehydrogenase, monoamine oxidase 
B, catalase, superoxide dismutase, trimethylamine N-oxidase, 
dihydropyrimidine dehydrogenase; and (e) cytochrome P450 
enzymes, such as CYP1A1, CYP2A6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1, CYP3A5, and many others 
(Kalow and Grant 2001). Polymorphic variants in these genes 
can induce changes in drug metabolism altering the efﬁ  cacy 
and safety of the prescribed drugs. Drug metabolism includes 
phase I reactions (ie, oxidation, reduction, hydrolysis) and 
phase II conjugation reactions (ie, acetylation, glucuronida-
tion, sulfation, methylation). The typical paradigm for the 
pharmacogenetics of phase I drug metabolism is represented 
by the cytochrome P450 enzymes, a superfamily of micro-
somal drug-metabolizing enzymes. P450 enzymes represent 
a superfamily of heme-thiolate proteins widely distributed in 
bacteria, fungi, plants and animals. The P450 enzymes are 
encoded in genes of the CYP superfamily and act as terminal 
oxidases in multicomponent electron transfer chains which 
are called P450-containing monooxigenase systems. Some 
of the enzymatic products of the CYP gene superfamily can 
share substrates, inhibitors and inducers whereas others are 
quite speciﬁ  c for their substrates and interacting drugs (Ne-
bert and Jorge-Nebert 2002; Evans and McLeod 2003).
The principal enzymes with polymorphic vari-
ants involved in phase I reactions are the following: 
CYP3A4/5/7, CYP2E1, CYP2D6, CYP2C19, CYP2C9, 
CYP2C8, CYP2B6, CYP2A6, CYP1B1, CYP1A1/2, 
epoxide hydrolase, esterases, NQO1 (NADPH-quinone 
oxidoreductase), DPD (dihydropyrimidine dehydrogenase), 
ADH (alcohol dehydrogenase), and ALDH (aldehyde 
dehydrogenase). The microsomal, membrane-associated, 
P450 isoforms CYP3A4, CYP2D6, CYP2C9, CYP2C19, 
CYP2E1, and CYP1A2 are responsible for the oxidative 
metabolism of more than 90% of marketed drugs; and 
CYP3A4 metabolizes more drug molecules than all other 
isoforms together. Major enzymes involved in phase II reac-
tions include the following: UGTs (uridine 5’-triphosphate 
glucuronosyl transferases), TPMT (thiopurine methyl-
transferase), COMT (catechol-O-methyltransferase), HMT 
(histamine methyl-transferase), STs (sulfotransferases), 
GST-A (glutathion S-transferase A), GST-P, GST-T, GST-
M, NAT2 (N-acetyl transferase), NAT1, and others (Kalow 
and Grant 2001). Most of these polymorphic genes exhibit 
geographic and ethnic differences. These differences inﬂ  u-
ence drug metabolism in different ethnic groups in which 
drug dosage should be adjusted according to their enzymatic 
capacity, differentiating normal or extensive metabolizers 
(EMs), poor metabolizers (PMs) and ultrarapid metabolizers 
(UMs) (Cacabelos 2005a, b). 
It is very well known for many years the heterogeneity 
of AD and how apparently identical phenotypes assessed 
with international clinical criteria (NINCDS-ADRDA, 
DSM-IV, ICD-10) do not always respond to the same drugs 
(Cacabelos et al 2000a, b; Cacabelos 2005a, b). This may 
be due to different factors, including pharmacokinetic and 
pharmacodynamic properties of drugs, nutrition, liver func-
tion, concomitant medications, and individual genetic factors 
(Cacabelos 2005b). In fact, the therapeutic response of AD 
patients to conventional cholinesterase inhibitors is partially 
effective in only 10%–20% of the cases, with side-effects, 
intolerance, and non-compliance in more than 60% of the 
patients due to different reasons (eg, efﬁ  cacy, safety) (Gia-
cobini 2000, 2006; Cacabelos et al 2000b). Therefore, the 
individualization of therapy or pharmacological tailorization 
in AD and other CNS disorders is just a step forward of the 
longstanding goal of molecular pharmacogenomics taking 
advantage from the information and procedures provided by 
the sequencing of the entire human genome (International 
Human Genome Sequencing Consortium 2004).  
Several studies indicate that the presence of the 
APOE-4 allele differentially affects the quality and size of 
drug responsiveness in AD patients treated with cholinergic 
enhancers (tacrine, donepezil, rivastigmine) (Poirier 1999; 
Poirier et al 1995; Almqvist et al 2001). For example, 
APOE-4 carriers show a less signiﬁ  cant therapeutic response 
to tacrine (60%) than patients with no APOE-4 (Poirier et al 
1995). In another study the frequency of APOE-4 alleles Neuropsychiatric Disease and Treatment 2007:3(3) 322
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was higher in responders to a single oral dose of tacrine 
(Almqvist et al 2001). More than 80% of APOE-4(–) AD 
patients showed marked improvement after 30 weeks of 
treatment with tacrine, whereas 60% of APOE-4(+) carriers 
had a poor response (Poirier et al 1995). Others found no 
differences after 6 months of treatment with tacrine among 
APOE genotypes, but after 12 months the CIBIC scores 
revealed that APOE-4 carriers had declined more than the 
APOE-2 and APOE-3 patients, suggesting that a faster rate 
of decline was evident in the APOE-4 patients probably 
reﬂ  ecting that APOE-4 inheritance is a negative predictor 
of treatment of tacrine in AD (Sjögren et al 2001). It has 
also been shown that the APOE genotype may inﬂ  uence the 
biological effect of donepezil on APP metabolism in AD 
(Borroni et al 2002). Prospective studies with galantamine 
in large samples of patients in Europe (Aerssens et al 2001) 
and in USA (Raskind et al 2000) showed no effect of APOE 
genotypes on drug efﬁ  cacy, but a retrospective study with a 
small number of AD cases in Croatia showed the intriguing 
result of 71% responders to galantamine treatment among 
APOE-4 homozygotes (Babic et al 2004). MacGowan et al 
(1998) reported that gender is likely to be a more powerful 
determinant of outcome of anticholinesterase treatment than 
APOE status in the short term. In contrast, other studies do 
not support the hypothesis that APOE and gender are predic-
tors of the therapeutic response of AD patients to tacrine or 
donepezil (Rigaud et al 2002). In a recent study, Petersen 
et al (2005) showed that APOE-4 carriers exhibited a bet-
ter response to donepezil. Similar results have been found 
by Bizzarro et al (2006); however, Rigaud et al (2002) did 
not ﬁ  nd any signiﬁ  cant difference between APOE-4-related 
responders and non-responders to donepezil. An APOE-related 
differential response has also been observed in patients treated 
with other compounds devoid of acetylcholinesterase inhib-
iting activity (CDP-choline, anapsos) (Alvarez et al 1999; 
Alvarez et al 2000) suggesting that APOE-associated factors 
may inﬂ  uence drug activity in the brain either directly acting on 
neural mechanisms or indirectly inﬂ  uencing diverse metabolic 
pathways. To date, few studies have addressed in a prospective 
manner the impact of pharmacogenetic and pharmacogenomic 
factors on AD therapeutics; however, recent data indicate that 
the therapeutic response in AD is genotype-speciﬁ  c (Cacabelos 
et al 2000a, b; Cacabelos 2002a, b; Cacabelos 2003; Cacabelos 
et al 2004b;  Cacabelos 2005a, b). 
CYP2D6-related therapeutic response
The CYP2D6 enzyme, encoded by a gene that maps on 
22q13.1-13.2, catalyzes the oxidative metabolism of more than 
Figure 1 CYP2D6-related therapeutic response in Alzheimer’s disease. Cognitive performance in extensive (EM), intermediate (IM), poor (PM), and ultra-rapid metabolizers 
(UM) during treatment with a multifactorial (combination) therapy.
Notes and abbreviations: MMSE, Mini-Mental State Examination; 0, Baseline Score (prior to treatment); 1–12, 1–12 months of treatment; SD, standard deviation; X, mean 
(MMSE score).Neuropsychiatric Disease and Treatment 2007:3(3) 323
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100 clinically important and commonly prescribed drugs such 
as cholinesterase inhibitors (tacrine, donepezil, galantamine), 
antidepressants, neuroleptics, opioids, some β-blockers, class I 
antiarrhythmics, analgesics and many other drug categories, 
acting as substrates, inhibitors or inducers with which cholin-
esterase inhibitors may potentially interact, this leading to the 
outcome of ADRs (Cacabelos 2005a, b). The CYP2D6 locus 
is highly polymorphic, with more than 100 different CYP2D6 
alleles identiﬁ  ed in the general population showing deﬁ  cient 
(poor metabolizers, PM), normal (extensive metabolizers, 
EM) or increased enzymatic activity (ultra-rapid metabolizers, 
UM). Most individuals (> 80%) are EMs; however, remarkable 
interethnic differences exist in the frequency of the PM and 
UM phenotypes among different societies all over the world 
(Isaza et al 2000; Cacabelos and Takeda 2006). On the aver-
age, approximately 6.28% of the world population belongs to 
the PM category. Europeans (7.86%), Polynesians (7.27%), 
and Africans (6.73%) exhibit the highest rate of PMs, whereas 
Orientals (0.94%) show the lowest rate. The frequency of PMs 
among Middle Eastern populations, Asians, and Americans is 
in the range of 2%–3% (Isaza et al 2000; Cacabelos 2005a, b; 
Cacabelos and Takeda 2006). 
The most frequent CYP2D6 alleles in the European popu-
lation are the following: CYP2D6*1 (wild-type) (normal), 
CYP2D6*2 (2850C>T) (normal), CYP2D6*3 (2549A>del) 
(inactive), CYP2D6*4 (1846G>A) (inactive), CYP2D6*5 
(gene deletion) (inactive), CYP2D6*6 (1707T>del) (in-
active), CYP2D6*7 (2935A>C)  (inactive), CYP2D6*8 
(1758G>T) (inactive), CYP2D6*9 (2613-2615 delAGA) 
(partially active), CYP2D6*10 (100C>T) (partially active), 
CYP2D6*11 (883G>C) (inactive), CYP2D6*12 (124G>A) 
(inactive), CYP2D6*17 (1023C>T) (partially active), and 
CYP2D6 gene duplications (with increased or decreased 
enzymatic activity depending upon the genes involved) 
(Cacabelos 2007).  
EMs are more prevalent in AD (*1/*1, 49.42%; *1/*10, 
8.04%) (total AD-EMs: 57.47%) than in controls (*1/*1, 
44.12%; *1/*10, 0%) (total C-EMs: 44.12%). In contrast, IMs 
Figure 2 CYP2D6-related cognitive performance in Alzheimer’s disease. Correlation analysis among CYP2D6-related extensive (EM), intermediate (IM), poor (PM), and 
ultra-rapid metabolizers (UM) to characterize responders and non-responders during 1-year treatment period with a multifactorial therapy.Neuropsychiatric Disease and Treatment 2007:3(3) 324
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Figure 3 CYP2D6-related therapeutic response in Alzheimer’s disease. Inﬂ  uence of CYP2D6 genotypes on cognitive performance during treatment with a multifactorial 
therapy (CDP-choline, 500 mg/day; piracetam, 1600 mg/day; nicergoline, 5 mg/day; donepezil, 5 mg/day).
(a) Extensive Metabolizers (EM); (b) Intermediate Metabolizers (IM); Poor Metabolizers (PM); (d) Ultra-rapid Metabolizers (UM).
(c)
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are more frequent in controls (41.18%) than in AD (25.29%), 
especially the *1/*4 (C: 23.53%; AD: 12.64%) and *4/*10 
genotypes (C: 5.88%; AD: 1.15%). The frequency of PMs 
was similar in AD (9.20%) and controls (8.82%), and UMs 
were more frequent among AD cases (8.04%) than in controls 
(5.88%) (Cacabelos 2007). 
The genetic variation between AD and controls associated 
with CYP2D6 genotypes is 13.35% in EMs, 15.89% in IMs, 
0.38% in PMs, and 2.16% in UMs, with an absolute genetic 
variation of 31.78% between both groups, suggesting that 
this genetic difference might inﬂ  uence AD pathogenesis and 
therapeutics (Cacabelos 2007).
In the ﬁ  rst CYP2D6-related pharmacogenetic study 
with a combination therapy (donepezil + CDP-choline 
+ piracetam + nicergoline) in AD, EMs improved their 
cognitive function (MMSE score) from 21.58 ± 9.02 at 
baseline to 23.78 ± 5.81 after 1-year treatment (r = +0.82; 
a Coef. = +20.68; b Coef.: +0.4). IMs also improved from 
21.40 ± 6.28 to 22.50 ± 5.07 (r = +0.96; a Coef. = +21.2; 
b Coef. = +0.25), whereas PMs and UMs deteriorate from 
20.74 ± 6.72 to 18.07 ± 5.52 (r = –0.97; a Coef. = +21.63; 
b Coef. = –0.59), and from 22.65 ± 6.76 to 21.28 ± 7.75 (r 
= –0.92; a Coef. = +23.35; b Coef. = –0.36), respectively. 
According to these results, PMs and UMs were the worst 
responders, showing a progressive cognitive decline with 
no therapeutic effect, and EMs and IMs were the best 
responders, with a clear improvement in cognition after 
1 year of treatment (Figures 1, 2). Among EMs, AD pa-
tients harbouring the *1/*10 genotype (r = +0.97; a Coef. 
= +19.27; b Coef. = +0.55) responded better than patients 
with the *1/*1 genotype (r = +0.44; a Coef .= +22.10; b 
Coef. = +0.25). The best responders among IMs were the 
*1/*3 (r = +0.98; a Coef. = +20.65; b Coef. = 1.18), *1/*6 
(r = 0.93; a Coef. = +22.17; b Coef. = +0.44) and *1/*5 
genotypes (r = +0.70; a Coef. = +19.96; b Coef. = +0.25), 
whereas the *1/*4, *10/*10, and *4/*10 genotypes were 
poor responders. Among PMs and UMs, the poorest re-
sponders were carriers of the *4/*4 (r = –0.98; a Coef. = 
+19.72; b Coef. = –0.91) and *1xN/*1 genotypes (r = –0.97; 
a Coef. = +24.55; b Coef. = –0.98), respectively (Figure 3). 
The CYP2D6-related therapeutic responses can be modiﬁ  ed 
by the presence of the APOE-4/4 genotype which converts 
EMs and IMs in poor responders (Cacabelos 2007).
From this study, we can conclude the following: (1) 
there is an accumulation of AD-related genes of risk in 
PMs and UMs; (2) PMs and UMs tend to show higher 
transaminase activities than EMs and IMs; (3) EMs and IMs 
are the best responders, and PMs and UMs are the worst 
responders to a combination therapy with cholinesterase 
inhibitors, neuroprotectants, and vasoactive substances 
(Figures 1, 2, 3); (4) EMs and IMs can be converted into 
poor responders by the presence of the APOE-4/4 genotype; 
and (5) the pharmacogenetic response in AD appears to be 
dependent upon the networking activity of genes involved 
in drug metabolism and genes involved in AD pathogenesis 
(Cacabelos 2007).
Taking into consideration the available data, it might be 
inferred that at least 15% of the AD population may exhibit an 
abnormal metabolism of cholinesterase inhibitors and/or other 
drugs which undergo oxidation via CYP2D6-related enzymes. 
Approximately 50% of this population cluster would show an 
ultrarapid metabolism, requiring higher doses of cholinesterase 
inhibitors to reach a therapeutic threshold, whereas the other 
50% of the cluster would exhibit a poor metabolism, displaying 
potential adverse events at low doses. If we take into account 
that approximately 60%–70% of therapeutic outcomes depend 
upon pharmacogenomic criteria (eg, pathogenic mechanisms 
associated with AD-related genes), it can be postulated that 
pharmacogenetic and pharmacogenomic factors are respon-
sible for 75%–85% of the therapeutic response (efﬁ  cacy) in 
AD patients treated with conventional drugs (Cacabelos et al 
2000a, b; Cacabelos 2002a, b; Cacabelos 2003; Cacabelos 
et al 2004c; Cacabelos 2005a, b; Cacabelos 2006; Cacabelos 
2007). Of particular interest are the potential interactions of 
cholinesterase inhibitors with other drugs of current use in 
patients with AD, such as antidepressants, neuroleptics, antiar-
rhythmics, analgesics, and antiemetics which are metabolized 
by the cytochrome P450 CYP2D6 enzyme (Bernard et al 
2006). Although most studies predict the safety of donepezil 
and galantamine, as the two principal cholinesterase inhibitors 
metabolized by CYP2D6-related enzymes, no pharmacoge-
netic studies have been performed so far on an individual basis 
to personalize the treatment, and most studies reporting safety 
issues are the result of pooling together pharmacological and 
clinical information obtained with conventional procedures. 
In certain cases, genetic polymorphism in the expression of 
CYP2D6 is not expected to affect the pharmacodynamics of 
some cholinesterase inhibitors because major metabolic path-
ways are glucuronidation, O-demethylation, N-demethylation, 
N-oxidation, and epimerization. However, excretion rates 
are substantially different in EMs and PMs. For instance, in 
EMs, urinary metabolites resulting from O-demethylation of 
galantamine represent 33.2% of the dose compared with 5.2% 
in PMs, which show correspondingly higher urinary excretion 
of unchanged galantamine and its N-oxide (Mannens et al 
2002). Therefore, still there are many unanswered questions Neuropsychiatric Disease and Treatment 2007:3(3) 327
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regarding the metabolism of cholinesterase inhibitors and their 
interaction with other drugs (potentially leading to ADRs) 
which require pharmacogenetic elucidation. 
Conclusions
Donepezil is a piperidine-derivative reversible AChEI that 
enhances cholinergic neurotransmission and may have other 
non-cholinergic actions with potential beneﬁ  t for dementia 
(Table 2). Main pharmacological properties of donepezil include 
the following (Tables 1): (1) after oral ingestion, peak plasma 
concentrations are achieved in 3–5 hours; (2) absortion is not 
affected by food; (3) linear pharmacokinetics over a dose range 
of 1–10 mg/day; (4) steady-state plasma concentration reached 
in 14–21 days with daily dosing; (5) mean steady-state plasma 
concentrations are dose proportional; (6) mean cerebral spinal 
ﬂ  uid/plasma concentration is 0.157; (7) 96% of circulating done-
pezil is protein bound; (8) elimination half-life is approximately 
70 hours; (9) it is mostly excreted unchanged in urine; (10) there is 
some CYP3A4- and CYP2D6-related metabolism; (11) there are 
not signiﬁ  cant drug interactions; (12) the most important ADRs 
associated with donepezil are body events (45%), cardiovascular 
(18%), digestive (34%), hematic and lymphatic (5%), metabolic 
and nutritional (6%), musculoskeletal (17%), nervous system 
(52%), respiratory system (22%), skin and appendages (14%), 
special senses (5%), urogenital (25%), and some other rare side 
effects (1%–2%) (Table 3); (12) donepezil is effective in mAD 
and sAD cases as well as in patients with VD, showing a modest 
improvement in cognition, behavior, and function (Table 2); and 
(13) the effects of donepezil are dose-dependent, with optimal 
effects in the range of 5–10 mg/day.
After 20 years of experience in AD therapeutics, we can 
conclude that the main causes of therapeutic failure with 
AChEIs in general and donepezil in particular in AD are the 
following: (1) the central cholinergic deﬁ  cit in AD is not the 
cause of the disease but the consequence of neurodegenera-
tion associated with complex pathogenic mechanisms involv-
ing many different genomic, proteomic, and metabolomic 
cascades; (2) pharmacokinetic and pharmacodynamic weak-
nesses of the AChEIs; (3) an out-of-date screening protocol 
(outcome measures) to evaluate drug efﬁ  cacy only relying on 
psychometric parameters, neglecting the fundamental utility 
of biological markers and/or predictors of neuroprotection in 
the long-term; (4) critical problems of patient recruitment not 
differentiating pure AD cases from cases of AD with cere-
brovascular component and/or other medical conditions; (5) 
differences in the genetic proﬁ  le of AD patients who exhibit 
a genotype-related therapeutic response (pharmacogenomics; 
efﬁ  cacy issues); and (6) pharmacogenetic problems associ-
ated with genes responsible for the metabolism of drugs 
(pharmacogenetics; safety issues).
Despite all these considerations, AChEIs may be of some 
utility in 20%–30% of AD patients, and in this selected 
cluster of moderate responders the AChEIs should be used 
until other better therapeutic alternatives are available. The 
potential efﬁ  cacy of donepezil in responders may be due to an 
adequate pharmacogenetic-pharmacogenomic proﬁ  le associ-
ated with cholinesterase inhibition and/or other mechanisms 
of action directly or indirectly linked to cholinergic regulation 
(ie, anti-oxidation, inhibition of neuronal excitotocity-related 
mechanisms, cerebrovascular regulation).
Some other conclusions can also be drawn, such as 
that: (a) AChEIs (and most anti-dementia drugs) do 
not appear to be cost-effective; (b) novelty criteria and 
marketing pressure are not good advisers for treatment 
shift from a drug to another (there is no clear evidence 
that one AChEI is better than another, but some AChEIs 
are more harmful than others); (c) some pharmacologi-
cal properties of donepezil might be beneficial in other 
forms of dementia and also in some other CNS disorders; 
(d) multifactorial interventions with combination therapy 
(including donepezil in the cocktail) may be more effec-
tive in AD than monotherapies; (e) in any circumstance, 
the therapeutic response in AD depends largely on the 
genomic profile of the patients; (f) cholinesterase inhibi-
tors should be avoided in those AD patients in whom their 
genomic profile predict a poor therapeutic outcome; and 
(g) pharmacogenetics and pharmacogenomics studies can 
contribute to optimize therapeutics in the coming future 
by improving efficacy and safety and reducing costs.
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